https://www.selleckchem.com/products/bgb-290.html
Second-line treatment for immune thrombocytopenia (ITP) is not well reported for patients treated in real-world clinical settings. The purpose of this study was to compare outcomes of four second-line treatments for ITP. Included adult patients had at least two medical records containing ITP diagnoses and second-line eltrombopag, romiplostim, rituximab, or splenectomy. Date of treatment initiation or splenectomy was set as index date, between July 1, 2008, and March 31, 2017. Patients had first-line corticosteroid or intravenous immune
כמו
תגובה
לַחֲלוֹק
